Skip to content

US · ICCC · BIOTECHNOLOGY

ImmuCell Corporation (ICCC) intrinsic value and stock valuation

$10.92as of 2026-11-21 · Mkt cap 99.51M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

ImmuCell Corporation DCF and intrinsic value

InvestorsCraft values ICCC with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from ICCC’s statements →

ImmuCell Corporation Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Portland, ME 04103 immucell.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$27.6M+12.5% 5y CAGRd
20112025
Net income
-$-1.04M
20112025
Free cash flow
$1.22M
20112025
Total equity
$27.1M-0.9% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$27.6M$26.5M$17.5M$18.6M$19.2M
Operating income$1.65M-$-1.64M-$-5.75M-$-2.3M$260K
Net income-$-1.04M-$-2.16M-$-5.77M-$-2.49M-$-80K
EPSd-$-115.17K-$-264.38K-$-744.52K-$-321.29K-$-10.54K
Operating cash flow$2.48M$360K-$-4.67M-$-1.54M$950K
Capital expenditure-$-1.25M-$-470K-$-1.89M-$-3.98M-$-2.61M
Free cash flow$1.22M-$-110K-$-6.57M-$-5.52M-$-1.65M
Total assets$42.5M$45.1M$43.8M$44.9M$44.5M
Total debt$13.2M$15.1M$16.7M$12.5M$10.3M
Net debt$9.39M$11.3M$15.7M$6.69M$90K
Total equity$27.1M$27.5M$25M$30.4M$32.6M
Cash and short-term investments$3.81M$3.76M$980K$5.79M$10.2M
Income statement
20252024202320222021
Revenue$27.6M$26.5M$17.5M$18.6M$19.2M
Cost of revenue$16.2M$18.6M$13.1M$10.9M$10.6M
Gross profit$11.5M$7.94M$4.4M$7.65M$8.66M
Research and development expenses$3.04M$3.9M$4.39M$4.49M$4.17M
Selling, general and administrative expenses$6.75M$5.68M$5.22M$5.45M$4.23M
Other expenses$0.00$0.00$530K$0.00$0.00
Operating expenses$9.8M$9.58M$10.1M$9.95M$8.4M
Cost and expenses$26M$28.1M$23.2M$20.9M$19M
Interest income$160K$80K$100K$150K$20K
Interest expense$440K$570K$450K$350K$310K
Depreciation and amortization$2.73M$2.69M$2.72M$2.49M$2.46M
Ebitda$2.14M$1.07M-$-2.5M$350K$2.7M
Operating income$1.65M-$-1.64M-$-5.75M-$-2.3M$260K
Total other income/expenses, net-$-2.68M-$-510K-$-20K-$-190K-$-330K
Income before tax-$-1.03M-$-2.15M-$-5.77M-$-2.49M-$-70K
Income tax expense$10K$10K$0.00$10K$10K
Net income-$-1.04M-$-2.16M-$-5.77M-$-2.49M-$-80K
Weighted average shares outstanding$9.03M$8.17M$7.7M$7.75M$7.59M
Weighted average diluted shares outstanding$9.03M$8.17M$7.75M$7.75M$7.59M
Balance sheet
20252024202320222021
Cash and short-term investments$3.81M$3.76M$980K$5.79M$10.2M
Net receivables$3.42M$3.81M$2.19M$1.8M$2.72M
Inventory$9.27M$7.11M$7.81M$6.04M$3.09M
Total current assets$16.9M$15M$11.5M$14M$16.3M
Property, plant and equipment, net$0.00$29.9M$32.2M$30.6M$28M
Goodwill and intangible assets$100K$110K$130K$150K$170K
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$25.6M$30.1M$32.3M$30.9M$28.2M
Total assets$42.5M$45.1M$43.8M$44.9M$44.5M
Accounts payable$800K$940K$890K$790K$750K
Short-term debt$1.7M$1.93M$2.07M$1.07M$920K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$3.98M$4.41M$4.2M$3.07M$2.53M
Long-term debt$11.5M$13.2M$14.6M$11.4M$9.35M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$11.5M$13.2M$14.6M$11.4M$9.35M
Capital lease obligations$4.1M$4.56M$4.72M$2.25M$1.14M
Total liabilities$15.5M$17.6M$18.8M$14.5M$11.9M
Common stock$910K$900K$780K$780K$780K
Retained earnings-$-15.2M-$-14.16M-$-12.01M-$-6.23M-$-3.74M
Accumulated other comprehensive income (loss)$0.00$0.00-$0.00-$0.00-$0.00
Total equity$27.1M$27.5M$25M$30.4M$32.6M
Total investments$0.00$0.00$0.00$0.00-$0.00
Total debt$13.2M$15.1M$16.7M$12.5M$10.3M
Net debt$9.39M$11.3M$15.7M$6.69M$90K
Cash flow statement
20252024202320222021
Net income-$-1.04M-$-2.16M-$-5.77M-$-2.49M-$-80K
Depreciation and amortization$2.73M$2.69M$2.72M$2.49M$2.46M
Stock-based compensation$300K$330K$370K$270K$140K
Change in working capital-$-2.05M-$-410K-$-2.27M-$-1.83M-$-1.62M
Accounts receivable$350K-$-1.59M-$-430K$940K-$-900K
Inventory-$-2.15M$700K-$-1.77M-$-2.95M-$-1M
Accounts payable-$-200K$360K$160K$0.00$245.8M
Net cash provided by operating activities$2.48M$360K-$-4.67M-$-1.54M$950K
Investments in property, plant and equipment-$-1.25M-$-470K-$-1.89M-$-3.98M-$-2.61M
Acquisitions, net$0.00$0.00$0.00$10K$20K
Net cash used for investing activities-$-1.21M-$-460K-$-1.89M-$-3.96M-$-1.6M
Common stock issued$350K$4.36M$0.00$30.7M$4.23M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-1.21M$2.88M$1.75M$1.11M$3.88M
Net change in cash$50K$2.78M-$-4.81M-$-4.39M$3.24M
Cash at end of period$3.81M$3.76M$980K$5.79M$10.2M
Operating cash flow$2.48M$360K-$-4.67M-$-1.54M$950K
Capital expenditure-$-1.25M-$-470K-$-1.89M-$-3.98M-$-2.61M
Free cash flow$1.22M-$-110K-$-6.57M-$-5.52M-$-1.65M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About ImmuCell Corporation

        ImmuCell Corporation functions as an animal health enterprise, specializing in the creation, manufacturing, and commercialization of offerings aimed at improving the vitality and output of dairy and beef cattle, serving both the U.S. domestic market and international regions. Among its key products is First Defense, an orally administered preventative designed to combat scours in newborn dairy and beef calves. The company also provides Tri-Shield First Defense, a passive antibody treatment effective against E. coli, coronavirus, and rotavirus. Additionally, ImmuCell offers the California Mastitis Test, a diagnostic instrument used to quantify somatic cell counts in milk and identify which specific udder quarter may be affected by mastitis. Its Dual-Force First Defense product, incorporating a whey protein concentrate, caters to the nutritional and animal feed supplement industries. Currently under development is Re-Tain, a Nisin-based intramammary therapy targeting subclinical mastitis in lactating dairy cows. The company primarily distributes its products through a network of animal health distributors. ImmuCell Corporation was established in 1982 and is based in Portland, Maine.

        CEO
        F. Olivier Te Boekhorst
        Employees
        73
        Beta
        0.57

        Explore

        Frequently asked questions

        What is the intrinsic value of ImmuCell Corporation (ICCC)?

        ImmuCell Corporation (ICCC) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is ICCC undervalued?

        ICCC trades at a price of $10.92 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.